|
Balance Sheet Cash Flow Statement 3200 Walnut St. Boulder, CO 80301 CO Tel. 303-381-6600 Toll Free 877-633-2436 Fax 303-386-1390 |
Type: Public
On the web:
http://www.arraybiopharma.com
Employees:
355
Employee growth: (8.0%)
Array BioPharma is discovering it's best to be your own boss. Once devoted to discovering drug candidates for other firms, the company is increasingly focused on its own drug development efforts in the areas of cancer and inflammatory disease. Candidates in early clinical trials include potential therapies for breast cancer (ARRY-543) and rheumatoid arthritis (ARRY-162). Array has also out-licensed some cancer programs to AstraZeneca and Genentech; ARRY-886, developed with AstraZeneca, is in clinical trials for melanoma. Drug discovery services for third parties still account for a big chunk of business; Array has R&D agreements with InterMune, Ono Pharmaceutical, Celgene, and others.
Key numbers for fiscal year ending June, 2009:
Sales: $25.0M
One year growth: (13.3%)
Net income: ($127.8)M
Officers:
Chairman: Kyle A. Lefkoff
CEO and Director: Robert E. (Bob) Conway
President, Chief Scientific Officer, and Director: Kevin Koch
Competitors:
ArQule
Theravance
Vertex Pharmaceuticals
